Showing results (101-110 of 141) with videos related to
Sort By:
Pageof 15
Hepato-Gastroenterology|December 13, 2005
Combination of enprostil and cimetidine is more effective than cimetidine alone in treating gastric ulcer: prospective multicenter randomized controlled trialHiroaki Murata, Sunao Kawano, Shingo Tsuji, et al.Journal of Vascular and Interventional Radiology : JVIR|March 7, 2021
Vessel Occlusion using Hydrogel-Coated versus Nonhydrogel Embolization Coils in Peripheral Arterial Applications: A Prospective, Multicenter, Randomized TrialNorio Hongo, Hiro Kiyosue, Shinichi Ota, et al.Liver Cancer|June 23, 2025
Comprehensive Analysis of Radiologic Cancer-Free Status through Various Treatment Approaches in Advanced-Stage Hepatocellular CarcinomaKeisuke Koroki, Sadahisa Ogasawara, Ryo Izai, et al.Scientific Reports|July 17, 2023
Estimation of the effect of atezolizumab plus bevacizumab on pulmonary arterial hypertension using computed tomography in HCC patientsTakayuki Kondo, Kisako Fujiwara, Miyuki Nakagawa, et al.Liver Cancer|June 24, 2026
Disease Complexity and Nodule-Specific Responses to Atezolizumab plus Bevacizumab in Advanced Hepatocellular CarcinomaSae Yumita, Sadahisa Ogasawara, Makoto Fujiya, et al.Investigational New Drugs|September 12, 2017
Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatmentSadahisa Ogasawara, Tetsuhiro Chiba, Yoshihiko Ooka, et al.Scientific Reports|August 28, 2023
Potential of circulating receptor-interacting protein kinase 3 levels as a marker of acute liver injuryTakayuki Kondo, Kentaro Fujimoto, Kisako Fujiwara, et al.Biochemical Pharmacology|February 27, 2025
MEGF6 knockdown ameliorates lenvatinib-induced muscle differentiation suppression and enhances the antitumor effect of lenvatinib on hepatocellular carcinomaNa Qiang, Junjie Ao, Masato Nakamura, et al.Journal of Gastroenterology|April 7, 2024
Clinical risk factors for portal hypertension-related complications in systemic therapy for hepatocellular carcinomaKisako Fujiwara, Takayuki Kondo, Kentaro Fujimoto, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|May 3, 2025
Evaluating two rechallenge strategies of immune checkpoint inhibitors: Durvalumab plus tremelimumab in advanced hepatocellular carcinomaTakuya Yonemoto, Sadahisa Ogasawara, Naoya Kanogawa, et al.Pageof 15